Safety of prolonged, repeated administration of a pulmonary formulation of tissue plasminogen activator in mice

Pulmonary Pharmacology and Therapeutics

Volumn 23, Issue 2, 2010, Pages 107-114

  Lackowski, Nicholas P ^a   Pitzer, Josh E ^a   Tobias, Meghan ^b   Van Rheen, Zachary ^b   Nayar, Rajiv ^c   Mosharaff, Mitra ^c   Stringer, Kathleen A ^a,b,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c HTD Biosystems   (United States)

Author keywords

Experimental lung injury; Fibrinolysis; Gender differences; Lung clearance; Plastic bronchitis; Pulmonary drug delivery; Therapeutic protein

Indexed keywords

FIBRIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT RESPIRATORY DISTRESS SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BRONCHITIS; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FIBROSING ALVEOLITIS; HEMATOCRIT; HISTOPATHOLOGY; LONG TERM CARE; LOW DRUG DOSE; LUNG CLEARANCE; LUNG HEMORRHAGE; LUNG LAVAGE; MALE; MOUSE; NEBULIZATION; NEBULIZER; NONHUMAN; PRIORITY JOURNAL; THORACOTOMY;

ADMINISTRATION, INHALATION; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; LUNG; LUNG DISEASES; MALE; MICE; SEX FACTORS; TISSUE DISTRIBUTION; TISSUE PLASMINOGEN ACTIVATOR;

EID: 75949113489     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2009.10.009     Document Type: Article

References (31)

1. Dellinger R.P., Levy M.M., Carlet J.M., Bion J., Parker M.M., Jaeschke R., et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock. Crit Care Med 2008 36 (2008) 296-327
2. Taskar V., and Coultas D. Exposures and idiopathic lung disease. Semin Respir Crit Care Med 29 (2008) 670-679
3. Goo H.W., Jhang W.K., Kim Y.H., Ko J.K., Park I.S., Park J.J., et al. CT findings of plastic bronchitis in children after a Fontan operation. Pediatr Radiol 38 (2008) 989-993
4. McClintock D., Zhuo H., Wickersham N., Matthay M.A., and Ware L.B. Biomarkers of inflammation, coagulation and fibrinolysis predict mortality in acute lung injury. Crit Care 12 (2008) R41
5. MacLaren R., and Stringer K.A. Emerging role of anticoagulants and fibrinolytics in the treatment of acute respiratory distress syndrome. Pharmacotherapy 27 (2007) 860-873
6. Do T.B., Chu J.M., Berdjis F., and Anas N.G. Fontan patient with plastic bronchitis treated successfully using aerosolized tissue plasminogen activator: a case report and review of the literature. Pediatr Cardiol 30 (2009) 352-355
7. Bringardner B.D., Baran C.P., Eubank T.D., and Marsh C.B. The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. Antioxid Redox Signal 10 (2008) 287-301
8. Sisson T.H., and Simon R.H. The plasminogen activation system in lung disease. Curr Drug Targets 8 (2007) 1016-1029
9. Renckens R., Roelofs J.J., Florquin S., de Vos A.F., Pater J.M., Lijnen H.R., et al. Endogenous tissue-type plasminogen activator is protective during Escherichia coli-induced abdominal sepsis in mice. J Immunol 177 (2006) 1189-1196
10. Renckens R., Roelofs J.J., Stegenga M.E., Florquin S., Levi M., Carmeliet P., et al. Transgenic tissue-type plasminogen activator expression improves host defense during Klebsiella pneumonia. J Thromb Haemost 6 (2008) 660-668
11. Stringer K.A., Dunn J.S., and Gustafson D.L. Administration of exogenous tissue plasminogen activator reduces oedema in mice lacking the tissue plasminogen activator gene. Clin Exp Pharmacol Physiol 31 (2004) 327-330
12. Ware L.B. Pathophysiology of acute lung injury and the acute respiratory distress syndrome. Semin Respir Crit Care Med 27 (2006) 337-349
13. Dunn J.S., Nayar R., Campos J., Hybertson B.M., Zhou Y., Manning M.C., et al. Feasibility of tissue plasminogen activator formulated for pulmonary delivery. Pharm Res 22 (2005) 1700-1707
14. Stringer K.A., Tobias M., Dunn J.S., Campos J., Van Rheen Z., Mosharraf M., et al. Accelerated dosing frequency of a pulmonary formulation of tissue plasminogen activator is well-tolerated in mice. Clin Exp Pharmacol Physiol 35 (2008) 1454-1460
15. Lijnen H.R., van Hoef B., Beelen V., and Collen D. Characterization of the murine plasma fibrinolytic system. Eur J Biochem 224 (1994) 863-871
16. Korninger C., and Collen D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost 46 (1981) 561-565
17. Serkova N.J., Van Rheen Z., Tobias M., Pitzer J.E., Wilkinson J.E., and Stringer K.A. Utility of magnetic resonance imaging and nuclear magnetic resonance-based metabolomics for quantification of inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol 295 (2008) L152-L161
18. Southam D.S., Dolovich M., O'Byrne P.M., and Inman M.D. Distribution of intranasal instillations in mice: effects of volume, time, body position, and anesthesia. Am J Physiol Lung Cell Mol Physiol 282 (2002) L833-L839
19. Loscalzo J., and Braunwald E. Tissue plasminogen activator. N Engl J Med 319 (1988) 925-931
20. Zhou Z., Kozlowski J., and Schuster D.P. Physiologic, biochemical, and imaging characterization of acute lung injury in mice. Am J Respir Crit Care Med 172 (2005) 344-351
21. Parker J.C., and Townsley M.I. Evaluation of lung injury in rats and mice. Am J Physiol Lung Cell Mol Physiol 286 (2004) L231-L246
22. Zwickl C.M., Hughes B.L., Piroozi K.S., Smith H.W., and Wierda D. Immunogenicity of tissue plasminogen activators in rhesus monkeys: antibody formation and effects on blood level and enzymatic activity. Fundam Appl Toxicol 30 (1996) 243-254
23. Card J.W., Carey M.A., Bradbury J.A., DeGraff L.M., Morgan D.L., Moorman M.P., et al. Gender differences in murine airway responsiveness and lipopolysaccharide-induced inflammation. J Immunol 177 (2006) 621-630
24. Carey M.A., Card J.W., Voltz J.W., Germolec D.R., Korach K.S., and Zeldin D.C. The impact of sex and sex hormones on lung physiology and disease: lessons from animal studies. Am J Physiol Lung Cell Mol Physiol 293 (2007) L272-L278
25. Shetty S., Padijnayayveetil J., Tucker T., Stankowska D., and Idell S. The fibrinolytic system and the regulation of lung epithelial cell proteolysis, signaling, and cellular viability. Am J Physiol Lung Cell Mol Physiol 295 (2008) L967-L975
26. Liu R.M. Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosis. Antioxid Redox Signal 10 (2008) 303-319
27. Nishiuma T., Sisson T.H., Subbotina N., and Simon R.H. Localization of plasminogen activator activity within normal and injured lungs by in situ zymography. Am J Respir Cell Mol Biol 31 (2004) 552-558
28. Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev 58 (2006) 1030-1060
29. Brain J.D. Inhalation, deposition, and fate of insulin and other therapeutic proteins. Diabetes Technol Ther 9 Suppl. 1 (2007) S4-S15
30. Folkesson H.G., Matthay M.A., Westrom B.R., Kim K.J., Karlsson B.W., and Hastings R.H. Alveolar epithelial clearance of protein. J Appl Physiol 80 (1996) 1431-1445
31. Sixt S.U., Beiderlinden M., Jennissen H.P., and Peters J. Extracellular proteasome in the human alveolar space: a new housekeeping enzyme?. Am J Physiol Lung Cell Mol Physiol 292 (2007) L1280-L1288